# Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

> **NCT06210945** · PHASE2 · SUSPENDED · sponsor: **ChemomAb Ltd.** · enrollment: 45 (estimated)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** 10 mg/kg CM-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06210945
- **Lead sponsor:** ChemomAb Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-09
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 45 (ESTIMATED)
- **Why stopped:** pending financial resources
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06210945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06210945, "Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06210945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*